• EdU Imaging Kits and the Translational RCC Response

  2026-08-22

  Syringin’s reported activity against renal cell carcinoma illustrates why proliferation must be measured as a mechanistic, pharmacodynamic endpoint. This thought-leadership article explains how EdU Imaging Kits (HF488) can connect S-phase DNA synthesis with pathway biology, combination-treatment decisions, and translational assay design.

• SAR131675: A VEGFR-3 Assay Strategy

  2026-08-22

  SAR131675 is a selective VEGFR-3 inhibitor for dissecting lymphangiogenic signaling, endothelial migration, and tumor-associated vascular remodeling. This article develops an evidence-aware assay strategy that connects VEGFR-3 biology with nicotine-related chronic kidney disease research without overstating translational certainty.

• H3K18 Lactylation Drives Astrocyte Pyroptosis

  2026-08-21

  Li et al. identify an H3K18 lactylation–NOD2 pathway that connects glycolytic remodeling with bilirubin-induced astrocyte pyroptosis and neuroinflammation. The study combines cellular, animal, chromatin, and transcriptomic evidence, providing a mechanistic framework for investigating bilirubin encephalopathy rather than merely describing its inflammatory consequences.

• Etomoxir: From CPT-1 Biology to Translational Strategy

  2026-08-20

  Etomoxir is more than a fatty acid oxidation reagent: it is a strategic perturbation tool for connecting mitochondrial substrate handling with immune function and disease phenotypes. This thought-leadership guide examines CPT-1 biology, concentration-dependent DGAT confounding, standardized whole-blood workflows, and the translational bridge to experimental autoimmune encephalomyelitis. It also outlines how R-(+)-Etomoxir can support rigorous fatty acid oxidation pathway research when paired with orthogonal flux, cytokine, viability, and tissue-level measurements.

• Frizzled5 Cholesterol Sensing Drives Wnt Signaling

  2026-08-20

  The reference study identifies Frizzled5 as a cholesterol-sensitive Wnt receptor that links lipid metabolism to receptor palmitoylation, membrane trafficking, and β-catenin signaling in pancreatic cancer. Its findings suggest that disrupting the cholesterol–Fzd5 interaction, including with 25-hydroxysterol, may restrain growth in Wnt-dependent tumors while providing a mechanistic framework for studying lipid-regulated morphogen signaling.

• Niclosamide Workflows for STAT3 Cancer Research

  2026-08-19

  Niclosamide supports mechanism-first cancer research by connecting STAT3 Tyr-705 phosphorylation, transcriptional effects, cell-cycle control, and apoptosis in one experimental workflow. This guide combines practical dosing, orthogonal readouts, and a carefully bounded lesson from a time-resolved natural-product bioassay.

• LGK-974: Practical PORCN Inhibitor Workflows

  2026-08-19

  LGK-974 provides a precise way to test whether Wnt-dependent phenotypes require PORCN-mediated ligand secretion, with applications spanning pathway assays, pancreatic cancer models, and translational study design. This guide connects nanomolar pathway control with practical dosing, orthogonal readouts, and troubleshooting strategies.

• RPN1, PD-L1, and Antitumor Immunity in TNBC

  2026-08-18

  The reference study identifies RPN1 as a glycosylation-linked regulator of PD-L1 stability and immune escape in triple-negative breast cancer. Its combination of molecular, cellular, immune, and in vivo analyses supports RPN1 loss as a potential strategy for improving anti-PD-1 responses, while also highlighting the need for further validation.

• GLT-1, CB1-CREB, and TBI: Study Insights

  2026-08-18

  A 2025 Biomolecules study identifies an astrocyte-centered mechanism linking post-traumatic 2-AG elevation to reduced GLT-1 expression, glutamate excitotoxicity, neuronal apoptosis, and cognitive dysfunction. Using controlled cortical impact, CB1 antagonism, MAGL inhibition, behavioral testing, and molecular assays, the work positions the CB1-CREB-GLT-1 axis as a mechanistic target for TBI research.

• Charge-Reversed Exosomes for Cartilage Gene Delivery

  2026-08-17

  Zhang and colleagues engineered cationic, charge-reversed exosomes that penetrate negatively charged cartilage and deliver eGFP mRNA to deeply located chondrocytes in human explants and an osteoarthritis mouse model. The study identifies reversible electrostatic interactions with cartilage glycosaminoglycans as a practical design principle for nonviral, tissue-targeted mRNA delivery.

• Thapsigargin for Reliable Calcium and Cell Assays

  2026-08-17

  Learn how Thapsigargin (SKU B6614) can standardize calcium perturbation, endoplasmic reticulum stress research, apoptosis assays, and cell viability workflows. This scenario-driven guide connects product handling data with practical assay design and recent mechanistic evidence.

• Targeted Amikacin Delivery into Mycobacterial Granulomas

  2026-08-16

  The reference study investigated monocyte-derived dendritic cells as carriers for FITC-labeled amikacin in mice with disseminated Mycobacterium avium infection. Its central finding was that loaded cells delivered detectable antibiotic cargo to granulomas without evidence of systemic amikacin distribution or increased MCP-1/CCR2 inflammatory markers, supporting a site-directed strategy that still requires therapeutic and safety validation.

• Ribociclib pH Interaction: A QbD Micro-Dissolution Study

  2026-08-15

  This study integrates Analytical Quality by Design with a biorelevant micro-dissolution model to examine whether physiologic pH shifts associated with acid-reducing therapy meaningfully alter ribociclib succinate solubility. Although solubility decreased after gastric-to-intestinal pH transitions, the authors concluded that the changes were unlikely to produce a significant absorption impact, while emphasizing the value of pH-shift testing during early formulation assessment.

• Pioglitazone: PPARγ Agonist Research Workflows

  2026-08-14

  Pioglitazone links metabolic transcriptional control with macrophage-polarization and tissue-protection assays. This practical guide covers compound preparation, DSS colitis workflows, beta-cell studies, neuroinflammation models, and troubleshooting strategies for more reproducible PPARγ research.

• SAR131675: VEGFR-3 Inhibition Workflows

  2026-08-14

  SAR131675 is a selective VEGFR-3 inhibitor for separating VEGFC-driven lymphatic, endothelial, and macrophage responses in cell, biochemical, and disease-model studies. This guide translates its potency, selectivity, formulation constraints, and hepatic fibrosis evidence into practical workflows and troubleshooting decisions.

8409 records 1/561 page Next 12345 下5页 Last page